Viking Therapeutics Reports Increased Q3 Net Loss Driven by Rising R&D Expenses
Viking Therapeutics (VKTX) reported a significant increase in its third-quarter net loss, which reached $183.2 million with a GAAP earnings per share of -$1.55. This represents more than a doubling of the $90.8 million net loss recorded during the same period last year. The widened deficit is primarily attributed to a surge in research and development (R&D) expenses as the obesity drug developer continues to advance its clinical pipeline. While higher spending reflects intensive investment in future product candidates, it has significantly impacted the company's short-term profitability.
Tickers: $VKTX
Topics: biotechnology earnings report net loss R&D expenses
Read the full article at Seeking Alpha
Part of the story Viking Therapeutics Reports Q3 GAAP EPS of -$1.55, Missing Estimates by $0.50 (3 articles)